China Approves Subcutaneous Leqembi for Early Alzheimer's Treatment

Chinese regulators have granted approval for the subcutaneous injection form of lecanemab (Leqembi) to serve as an initial therapy for patients diagnosed with early-stage Alzheimer's disease.

3 Sept, 04:00 — 3 Sept, 04:00

Post Share

Sources

Showing 1 of 1 sources

taiwan-newsMostly Factual13h ago

LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China - Taiwan News

LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China Taiwan News

Read full article →

China Approves Subcutaneous Leqembi for Early Alzheimer's Treatment

Sources

LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China - Taiwan News

Related Stories

UNICEF Report Reveals Millions of Children Face Annual Online Sexual Abuse

Jennifer Aniston and Boyfriend Discuss His Past Paralysis Battle

Pentagon Issues Immediate Testosterone Screening Guidelines for Troops

Toxic Wildfire Haze Spreads Across Southeast Asia Amid Super El Niño